Adherium (ASX: ADR) – respiratory medical devices developer

ABOUT COMPANY

Adherium (ADR) (https://www.adherium.com/) provides digital health solutions and is a global leader in connected respiratory medical devices. It offers Hailie, an asthma and COPD medication adherence solution for patients with chronic respiratory diseases. The company also has a series of new asthma and COPD sensors in development, which will enable the capture of physiological measures with their existing capabilities.

Hailie’s cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient’s prescribed inhaler. Hailie’s clinically proven, unique sensors capture when and how an inhaler is being used, radically improving adherence and patient self-management. This enables timely interventions and tailored treatments to improve health outcomes and greatly reduce hospital admissions.

Hailie is the only FDA 510(k) cleared drug agnostic digital sensor available today to offer physiological data insights on inhaler technique.

In September 2021, the company received the first US FDA 510(k) clearance of its Hailie® sensors with physiological parameters for AstraZeneca’s Symbicort® inhalers.

In July 2022, it received US FDA 510(k) clearance to market connecting GlaxoSmithKline’s Ellipta® inhaler users with its second next generation Hailie® sensor, designed for use with the Breo®, Anoro®, Incruse® , Trelegy® and Arnuity® Ellipta® dry powder inhalers (DPIs).

CAPITAL STRUCTURE

In March 2021, the company completed an $18m capital raise at 1.5c, supported by the commercial partners, who have again supported the $13.5m raise in September 2022.

New CEO appointed in March 2024 is less experienced.